These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 28870034

  • 41. The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
    Liu M, Gu W, Chen L, Li Y, Kuang H, Du J, Alvarez A, Lauand F, Souhami E, Zhang J, Xu W, Du Q, Mu Y, SoliD trial investigators.
    Diabetes Obes Metab; 2024 Sep; 26(9):3791-3800. PubMed ID: 38922731
    [Abstract] [Full Text] [Related]

  • 42. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
    Rosenstock J, Aronson R, Grunberger G, Hanefeld M, Piatti P, Serusclat P, Cheng X, Zhou T, Niemoeller E, Souhami E, Davies M, LixiLan-O Trial Investigators.
    Diabetes Care; 2016 Nov; 39(11):2026-2035. PubMed ID: 27527848
    [Abstract] [Full Text] [Related]

  • 43. Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trial.
    Kadowaki T, Jinnouchi H, Kaku K, Hersløv ML, Hyllested-Winge J, Nakamura S.
    J Diabetes Investig; 2016 Sep; 7(5):711-7. PubMed ID: 27182031
    [Abstract] [Full Text] [Related]

  • 44. Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open-label, controlled trial.
    Feng W, Chen W, Jiang S, Du L, Zhu D.
    Diabetes Obes Metab; 2021 Aug; 23(8):1786-1794. PubMed ID: 33783964
    [Abstract] [Full Text] [Related]

  • 45. Treat-to-target comparison between once daily biphasic insulin aspart 30 and insulin glargine in Chinese and Japanese insulin-naïve subjects with type 2 diabetes.
    Yang W, Xu X, Liu X, Yang G, Seino Y, Andersen H, Jinnouchi H.
    Curr Med Res Opin; 2013 Dec; 29(12):1599-608. PubMed ID: 23998560
    [Abstract] [Full Text] [Related]

  • 46. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial.
    Kaneto H, Takami A, Spranger R, Amano A, Watanabe D, Niemoeller E.
    Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():3-13. PubMed ID: 32072742
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S, Chow F, Choi DS, Taneda S, Hirao K, Park Y, Andersen TH, Gall MA, Christiansen JS, BOOST: Intensify All Trial Investigators.
    Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
    [Abstract] [Full Text] [Related]

  • 52. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, Bray R, Rodríguez Á.
    Lancet; 2021 Aug 14; 398(10300):583-598. PubMed ID: 34370970
    [Abstract] [Full Text] [Related]

  • 53. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial.
    Rodbard HW, Cariou B, Zinman B, Handelsman Y, Philis-Tsimikas A, Skjøth TV, Rana A, Mathieu C, BEGIN Once Long trial investigators.
    Diabet Med; 2013 Nov 14; 30(11):1298-304. PubMed ID: 23952326
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.